XSTOBINV
Market cap230mUSD
Dec 23, Last price
38.90SEK
1D
0.00%
1Q
-13.65%
Jan 2017
-48.27%
Name
BioInvent International AB
Chart & Performance
Profile
BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, Japan, and internationally. Its lead drug candidate is BI-1206 for the treatment of non-Hodgkin lymphoma and solid tumors. The company also develops tumor associated myeloid cells; cancer-associated regulatory T cells, which modulate the immune system; BT-001 in solid tumors; and BI-1808 and BI-1910, which are anti-TNFR2 antibodies for the treatment of solid tumors and cutaneous T-cell lymphoma. It has a strategic collaboration with Pfizer Inc. for the development of antibodies against tumor-associated myeloid cells; partnership and collaboration with Transgene to co-develskylinop multi-functional oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck for the clinical development of BI-1808. The Company was incorporated in 1996 and is based in Lund, Sweden.
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 71,461 -78.09% | 326,126 1,582.45% | 19,384 -86.85% | |||||||
Cost of revenue | 442,040 | 376,679 | 297,775 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | (370,579) | (50,553) | (278,391) | |||||||
NOPBT Margin | ||||||||||
Operating Taxes | 204 | (8,418) | 517 | |||||||
Tax Rate | ||||||||||
NOPAT | (370,783) | (42,135) | (278,908) | |||||||
Net income | (330,304) 869.06% | (34,085) -87.78% | (278,961) 263.85% | |||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | 30,959 | 279,849 | 900,794 | |||||||
BB yield | -2.48% | -14.19% | -36.00% | |||||||
Debt | ||||||||||
Debt current | 8,709 | 8,190 | 6,835 | |||||||
Long-term debt | 37,779 | 45,736 | 49,899 | |||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | (427,312) | (1,037,261) | (1,136,229) | |||||||
Cash flow | ||||||||||
Cash from operating activities | (341,691) | (41,227) | (245,843) | |||||||
CAPEX | (13,304) | (12,377) | (13,260) | |||||||
Cash from investing activities | 59,681 | (628,848) | (467,542) | |||||||
Cash from financing activities | 23,139 | 273,487 | 894,870 | |||||||
FCF | (371,434) | (45,063) | (298,396) | |||||||
Balance | ||||||||||
Cash | 1,068,699 | 1,017,481 | 1,082,829 | |||||||
Long term investments | (594,899) | 73,706 | 110,134 | |||||||
Excess cash | 470,227 | 1,074,881 | 1,191,994 | |||||||
Stockholders' equity | (2,449,529) | (2,122,342) | (2,082,928) | |||||||
Invested Capital | 3,782,500 | 3,755,427 | 3,478,282 | |||||||
ROIC | ||||||||||
ROCE | ||||||||||
EV | ||||||||||
Common stock shares outstanding | 65,798 | 61,521 | 54,161 | |||||||
Price | 18.96 -40.84% | 32.05 -30.63% | 46.20 0.65% | |||||||
Market cap | 1,247,523 -36.73% | 1,971,748 -21.20% | 2,502,238 89.84% | |||||||
EV | 820,211 | 934,487 | 1,366,009 | |||||||
EBITDA | (353,824) | (35,829) | (263,781) | |||||||
EV/EBITDA | ||||||||||
Interest | 638 | 650 | 517 | |||||||
Interest/NOPBT |